Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

Cellular Bioengineering is an accelerator of disruptive technologies with biomedical and biodefense applications. CBI searches for innovative and ingenious ideas which it can nurture and grow into mature products that will change the way the world operates. It has brought forward suites of technology at varying stages of development which have favorably impacted health care and homeland security in our country. It was founded in 2003 and headquartered in Honolulu, Hawaii.

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

Peking University Third Hospital is a private company headquartered in Beijing, China, that operates as a clinic.

Zhongshan Ophthalmic Center, part of Sun Yat-Sen University, is a Chinese company located in Guangzhou that operates hospitals.

The Schepens Eye Research Institute, Inc. operates as an eye research institute. It offers treatment for macular degeneration, diabetic retinopathy, glaucoma, other types of retinal and optic nerve degenerations and damage, dry eye and eye tissue transplants. The company was founded by Charles L. Schepens in 1950 and is headquartered in Boston, MA.

Precise Bio, Inc. is a company headquartered in Winston-Salem, NC. The firm operates regenerative medicine company. It was founded in 2015 by Aryeh Batt, Anthony Atala and Shay Soker. Aryeh Batt has been the CEO since the inception date.\nThe company says this about itself: Precise Bio develops regenerative medicine therapies that can transform patient care across a wide range of medical indications. Precise Bio's proprietary, break-through 4D bio-fabricating platform overcomes limitations of existing extrusion and ink-jet printers and paves the way for fabricating clinically viable tissues and organs. The Company's initial product pipeline is focused on ophthalmology and includes fabricated functional corneal grafts, intrastromal lenticules for treating keratoconus and vision correction, and a retinal implant for age-related macular degeneration. The Company also has earlier R&D programs to address unmet needs in additional medical indications, which are limited by the number of available donor tissues and organs, or where today's critical health problems can be solved using Precise Bio's naturally-based, hyper-accurate technology. Precise Bio was founded in 2016 by Prof. Anthony Atala, MD, Director of the Wake Forest Institute of Regenerative Medicine (WFIRM), Prof. Shay Soker, PhD, from WFIRM and Mr. Aryeh Batt, who developed the Company's transformative laser printing technology.

Carl Zeiss Meditec AG engages in the development, manufacture and marketing of medical devices. It operates through the Ophthalmic Devices and Microsurgery business segments. The Ophthalmic Devices segment includes intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment offers surgical microscopes and visualization solutions for neuro, ear, nose, and throat surgery, as well as the activities in the field of intraoperative radiotherapy. The company was founded on July 2002 and is headquartered in Jena, Germany.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Qingdao Zhonghao Biological Engineering Co., Ltd., established on 2010-06-02, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Cosmetic production;Production of hygiene products and single-use medical products;Experimental animal management.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Engineering and Technology Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;Sales of hygiene products and single-use medical products;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Disinfectant sales(Free of Hazardous Chemicals).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Part of MOH Holdings Pte Ltd., Singapore Health Services Pte Ltd. is a Singaporean company located in Singapore. The firm provides medical services. Ivy Ng is the CEO, in this role since 2012.

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.

Technolas Perfect Vision GmbH is a leading ophthalmology laser company, formed through a joint venture between Bausch + Lomb, and 20/10 PERFECT VISION AG. Technolas Perfect Vision has a full range of expertise in both femtosecond and excimer businesses. Current innovations focus on laser cataract surgery and the correction of presbyopia with the SUPRACOR™ laser treatment.

Itoham Foods Inc. manufactures and sells processed meat products. It specializes in the business of livestock farming and processing and meat processing, packing and sales. The company was founded by Denzo Ito in April 1928 and is headquartered in Nishinomiya, Japan.